Botulism produces an acute, afebrile, symmetric, descending flaccid paralysis that begins with cranial-nerve (oculobulbar) dysfunction in an alert patient with intact sensation. It must be differentiated from other disorders of the neuromuscular junction, peripheral nerve/root, motor neuron, muscle, and brainstem, as well as from neurotoxin exposures that impair cholinergic transmission. In a CDC series of 332 U.S. cases (>12 months of age), the illnesses most often on the treating physician’s differential were Guillain-Barré syndrome (GBS) and myasthenia gravis (MG); classic features were common, but “atypical” findings (e.g., paresthesias in 17%, elevated CSF protein in 13%, unilateral or ascending findings in a minority) were also reported, so no single feature excludes the diagnosis.^[1][2] Because treatment is time-critical and clinical, differentiation should proceed in parallel with, not before, antitoxin decision-making.

The following features, taken together, favor botulism over its mimics:^[3][4]

• Descending course beginning with the eyes/bulbar muscles (diplopia, ptosis, dysarthria, dysphagia), in contrast to the classically ascending pattern of GBS and tick paralysis.
• Symmetric weakness with preserved sensorium and no true sensory loss (paresthesias may rarely occur).
• Afebrile presentation (fever suggests a superimposed infection or an alternative diagnosis; it may occur in wound botulism).
• Autonomic/cholinergic signs: fixed or sluggish dilated pupils (mydriasis), dry mouth, ileus/constipation, urinary retention.
• Normal CSF (protein usually normal), normal neuroimaging, and a characteristic electrodiagnostic profile (below).

Detailed test performance and interpretation are covered in Laboratory findings and Other diagnostic studies.

In infant botulism (≈95% of confirmed cases occur before 6 months of age), the most common admitting diagnosis is sepsis; as hypotonia progresses, the differential broadens.^[14] Analyses of infants treated with BIG-IV but not confirmed to have botulism (“clinical mimics”) identify five recurring categories: spinal muscular atrophy type I, metabolic disorders, other infectious diseases, miscellaneous conditions, and probable (untested) infant botulism.^[15]

• Sepsis/meningoencephalitis — febrile, ill-appearing; positive cultures/CSF.^[16]
• Spinal muscular atrophy type I — longer history of weakness; spares extraocular muscles and sphincters (both characteristically involved in botulism); tongue fasciculations; SMN1 genetic testing.^[17]
• Transient neonatal / congenital myasthenic syndromes — onset in first days of life; maternal MG history (transient form); genetic testing.^[18]
• Metabolic/inborn errors, hypothyroidism — targeted metabolic and endocrine studies.^[19]
• GBS (including Miller Fisher) — rare in infancy, occurs in older children; elevated CSF protein and NCS/EMG distinguish it.^[20]

The edrophonium (Tensilon) test is generally not indicated in infants, because congenital MG is excluded by history and de novo autoimmune MG does not occur at this age.^[21]

Electrodiagnostic testing is the single most useful ancillary study for separating botulism from GBS, MG, and LEMS:^[22][23]

• Botulism: low resting CMAP amplitudes with normal motor conduction velocities and normal sensory studies; post-exercise facilitation and an incremental response to high-frequency (30–50 Hz) RNS — the most distinctive finding. Small, short-duration MUAPs on needle EMG. Facilitation in botulism is typically less pronounced than in LEMS but more persistent (minutes).
• MG: decrement on low-frequency (2–3 Hz) RNS; normal CMAP at rest; abnormal SFEMG jitter.^[24]
• LEMS: low resting CMAP with marked (>60–100%) post-exercise facilitation and decrement at low-frequency RNS.^[25]
• GBS: demyelinating features (prolonged distal latencies, conduction block, slowed velocities, prolonged/absent F-waves); electrodiagnostic abnormalities may be delayed in the first week.^[26]

Caveats: In botulism, incremental responses may be absent early or in severe cases, and both HFRNS and post-exercise facilitation lose sensitivity in the post-acute phase; a normal study does not exclude botulism.^[27][28]

• Use the descending vs. ascending distinction and pupillary/autonomic signs as first-line bedside discriminators; confirm with EDx and toxin testing.^[29]
• Do not delay antitoxin while excluding mimics; empiric treatment on clinical suspicion is standard.^[30]
• Search thoroughly for an attached tick (scalp, groin) in any acute ascending flaccid paralysis—removal is curative and averts unnecessary testing.^[31]
• Clustering of cases of symmetric descending paralysis strongly suggests botulism (or shellfish/toxin exposure) and mandates immediate public-health notification.^[32]

Template:WikiDoc Sources